These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 27847221)

  • 1. Chronic allograft injury: Mechanisms and potential treatment targets.
    Riella LV; Djamali A; Pascual J
    Transplant Rev (Orlando); 2017 Jan; 31(1):1-9. PubMed ID: 27847221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunosuppression for kidney transplantation: Where are we now and where are we going?
    Lim MA; Kohli J; Bloom RD
    Transplant Rev (Orlando); 2017 Jan; 31(1):10-17. PubMed ID: 28340885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapamycin for treatment of chronic allograft nephropathy in renal transplant patients.
    Stallone G; Infante B; Schena A; Battaglia M; Ditonno P; Loverre A; Gesualdo L; Schena FP; Grandaliano G
    J Am Soc Nephrol; 2005 Dec; 16(12):3755-62. PubMed ID: 16236802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Identifying the specific causes of kidney allograft loss: A population-based study].
    Lohéac C; Aubert O; Loupy A; Legendre C
    Nephrol Ther; 2018 Apr; 14 Suppl 1():S39-S50. PubMed ID: 29606262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive immunohistological analysis of the endothelin system in human kidney grafts.
    Frank K; Zeier M; Gross ML; Waldherr R; Ritz E; Amann K
    Nephrol Dial Transplant; 2006 May; 21(5):1365-72. PubMed ID: 16449275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calcineurin Inhibitor-Sparing Strategies in Renal Transplantation: Where Are We? A Comprehensive Review of the Current Evidence.
    Camilleri B; Bridson JM; Halawa A
    Exp Clin Transplant; 2016 Oct; 14(5):471-483. PubMed ID: 27213490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natural killer cells play a critical role in mediating inflammation and graft failure during antibody-mediated rejection of kidney allografts.
    Kohei N; Tanaka T; Tanabe K; Masumori N; Dvorina N; Valujskikh A; Baldwin WM; Fairchild RL
    Kidney Int; 2016 Jun; 89(6):1293-306. PubMed ID: 27165816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overcoming barriers to long-term graft survival.
    Kaplan B
    Am J Kidney Dis; 2006 Apr; 47(4 Suppl 2):S52-64. PubMed ID: 16567241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic allograft nephropathy.
    Najafian B; Kasiske BL
    Curr Opin Nephrol Hypertens; 2008 Mar; 17(2):149-55. PubMed ID: 18277147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
    Bumbea V; Kamar N; Ribes D; Esposito L; Modesto A; Guitard J; Nasou G; Durand D; Rostaing L
    Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between a change in donor kidney function and long-term allograft outcomes in kidney transplant recipients.
    Oh IH; Lee CH; Kim GH; Kang CM; Park JS
    Artif Organs; 2015 Mar; 39(3):254-9. PubMed ID: 25205383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kidney transplant recipients and the incidence of adverse reactions to cyclosporin.
    Tolou-Ghamari Z; Palizban AA
    Saudi Med J; 2004 Oct; 25(10):1499-500. PubMed ID: 15494834
    [No Abstract]   [Full Text] [Related]  

  • 13. Renin-Angiotensin System Blockage and Avoiding High Doses of Calcineurin Inhibitors Prevent Interstitial Fibrosis and Tubular Atrophy in Kidney Transplant Recipients.
    Sayin B; Canver B; Gurlek Demirci B; Colak T; Ozdemir BH; Haberal M
    Exp Clin Transplant; 2017 Feb; 15(Suppl 1):32-36. PubMed ID: 28260428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors of long-term graft loss in renal transplant recipients with chronic allograft dysfunction.
    Khalkhali HR; Ghafari A; Hajizadeh E; Kazemnejad A
    Exp Clin Transplant; 2010 Dec; 8(4):277-82. PubMed ID: 21143092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transplant capillaropathy and transplant glomerulopathy: ultrastructural markers of chronic renal allograft rejection.
    Ivanyi B
    Nephrol Dial Transplant; 2003 Apr; 18(4):655-60. PubMed ID: 12637631
    [No Abstract]   [Full Text] [Related]  

  • 16. Arteriosclerosis in zero-time biopsy is a risk factor for tacrolimus-induced chronic nephrotoxicity.
    Yagisawa T; Omoto K; Shimizu T; Ishida H; Tanabe K
    Nephrology (Carlton); 2015 Jul; 20 Suppl 2():51-7. PubMed ID: 26031587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subclinical Rejection Phenotypes at 1 Year Post-Transplant and Outcome of Kidney Allografts.
    Loupy A; Vernerey D; Tinel C; Aubert O; Duong van Huyen JP; Rabant M; Verine J; Nochy D; Empana JP; Martinez F; Glotz D; Jouven X; Legendre C; Lefaucheur C
    J Am Soc Nephrol; 2015 Jul; 26(7):1721-31. PubMed ID: 25556173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transplanting kidneys from CMV-seropositive donors to CMV-seronegative recipients is not associated with poorer renal allograft function or survival.
    McLaughlin K; Sandhu S; Wu C; Muirhead N; Hollomby D; Jevnikar A
    Nephrol Dial Transplant; 2005 Jan; 20(1):176-80. PubMed ID: 15572381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors for chronic rejection in renal allograft recipients.
    Kim HC; Suk J; Joo I; Park SB; Park KK; Cho WH; Park CH
    Transplant Proc; 1996 Jun; 28(3):1456-7. PubMed ID: 8658739
    [No Abstract]   [Full Text] [Related]  

  • 20. Long-term renal allograft recipients from South-east Asia in the pre-cyclosporin era.
    Tang S; Lui SL; Li FK; Lo WK; Chan TM; Lai KN
    Int J Artif Organs; 1999 Mar; 22(3):131-7. PubMed ID: 10357240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.